More news:
bellwetherreport.com: CytoGenix Sparks the Interest of the Bellwether Report
03:34 a.m. 10/01/2004 Provided by
Oct 01, 2004 (M2 PRESSWIRE via COMTEX) -- The Bellwether Report, has initiated coverage on CytoGenix Inc (CYGX), a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology.
CytoGenix announced the filing on Sept. 28, 2004, of a patent application with the U.S. Patent and Trademark Office for an invention titled A Novel Genomic Approach Identifies Bacterial DNA-Dependent RNA Polymerase as the Target of an Antibacterial Oligodeoxynucleotide, RBL1.
The urgent need for new classes of antimicrobial compounds with entirely new mechanisms of action, has given CytoGenix an opportunity to progress further into this industry, and hopefully soon begin utilizing their technology.
BWR will be keeping a close eye on CytoGenix to see how the markets react to this fresh corporate development.
The Bellwether Report, will continue researching this new development with CytoGenix Inc, if you would like to receive all corporate updates on the company feel free to visit, www.bellwetherreport.com .
The Bellwether Report, will continue scanning the markets for true emerging growth opportunities that will show subscribers optimal entry points with profitable exit points. If you are interested in receiving more information on the above mentioned companies feel free to sign up for a 3 month complimentary subscription to the #1 online investment resource www.bellwetherreport.com .
AI
